Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Prudential PLC — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while Prudential PLC trades at $23.79 (market cap $29.25B). The key difference: Prudential PLC is far larger — about 5.8× Oruka Therapeutics Inc. Common Stock's market cap, and Prudential PLC pays a 2.33% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Prudential PLC for 119 Days on average.
| ORKA | PUK | |
|---|---|---|
Market Cap | $5.08B | $29.25B |
Volume | 685,276 | 1,214,779 |
Sector | Health | Financials |
52-Week High | $113.08 | $33.61 |
52-Week Low | $26.19 | $23.54 |
Typical Hold Time | 0 Days | 119 Days |
Enterprise Value | $4.21B | $28.79B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Prudential (PUK) trades at $23.83, down 0.17% with a bearish technical signal. The company shows strong fundamentals with 2025 revenue of $27.39B and net income of $3.98B, supported by a 14.52% profit margin and attractive valuation ratios including a P/E of 8.38. Recent strategic moves include exiting emerging markets and focusing on core operations, with analyst consensus leaning positive despite mixed quarterly earnings performance.
The outlook remains cautiously optimistic given solid profitability and strategic repositioning, though risks include execution of the $3B capital rotation plan and market volatility. With 50% of analysts rating it Buy and technical indicators showing oversold conditions, the stock presents value potential for patient investors despite near-term bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
